M206 benralizumab for the treatment of refractory allergic bronchopulmonary aspergillosis

Allergic bronchopulmonary aspergillosis (ABPA) has varying degrees of disease activity, one of which is a refractory form with an inability to taper off systemic steroids. Additionally, azoles, through CYP3A4 inhibition, can increase concentrations of steroids and increase the risk of adverse effects.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research